Article Details

Canakinumab Plus Chemotherapy Show No OS Improvement in Advanced or Metastatic NSCLC

Retrieved on: 2021-03-09 21:33:45

Tags for this article:

Click the tags to see associated articles and topics

Canakinumab Plus Chemotherapy Show No OS Improvement in Advanced or Metastatic NSCLC. View article details on hiswai:

Excerpt

... EGFR- or ALK-positive tumors; and severe hypersensitivity reaction to monoclonal antibodies, taxanes, or excipients of docetaxel or canakinumab.

Article found on: www.targetedonc.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up